On 15 October 2021, ADVANCED BIOLOGICAL LABORATORIES SA (“ABL SA”) acquired 96.70% of the capital of ETABLISSEMENTS FAUVET GIREL (“EFG”), a “shell company” listed on Euronext Paris compartment C. ABL SA has carried out this transaction with the aim of developing new activities in the field of infectious disease genotyping diagnostic within EFG.
In accordance with the applicable regulations, ABL SA announced on 15 October 2021 its intention to proceed with the filing of a draft public tender offer without a squeeze-out.
The simplified public tender offer (the “Offer”) for ETABLISSEMENTS FAUVET-GIREL shares, initiated on 23 December 2021 by ADVANCED BIOLOGICAL LABORATORIES SA, closed on 7 January 2022. On the occasion of this Offer, ABL SA acquired 954 shares representing 0.38% of the capital and 0.38% of the voting rights of EFG. At the closing of the offer, ABL SA holds 243,481 EFG shares representing the equal number of voting rights, i.e. 97.08% of the capital and voting rights of this company.
Banque Delubac & Cie acted as presenting bank for the offer alongside Atout Capital, transaction adviser.